Your session is about to expire
← Back to Search
Behavioral Intervention
Technology-Assisted Conscientiousness Therapy for Multiple Sclerosis (TACT-MS Trial)
N/A
Waitlist Available
Research Sponsored by State University of New York at Buffalo
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline only
Awards & highlights
TACT-MS Trial Summary
This trial examines whether a phone app can help people be more conscientious with their health, and potentially improve employment outcomes.
Who is the study for?
This trial is for adults over 18 with Multiple Sclerosis (MS) who are currently working and have a low score on the NEO-FFI Conscientiousness test, indicating less conscientious behavior than average. People with substance abuse issues, psychiatric disorders, or neurological diseases other than MS cannot participate.Check my eligibility
What is being tested?
The study is testing a phone app designed to improve health management and work life for people with MS by boosting their conscientiousness—a personality trait linked to responsible and organized behavior.See study design
What are the potential side effects?
Since this intervention involves using an app rather than medication, traditional side effects are not expected. However, users may experience stress or frustration if they find it challenging to engage with the technology or adhere to its recommendations.
TACT-MS Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at baseline, week 12, and week 24
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline, week 12, and week 24
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Buffalo Vocational Monitoring Survey (BVMS): change from baseline to 12 weeks and from baseline to 24 weeks
Self -Reflection and Insight Scale (SRIS): change from baseline to 12 weeks and from baseline to 24 weeks
The Valued Living Questionnaire (VLQ): change from baseline to 12 weeks and from baseline to 24 weeks
Secondary outcome measures
Beck Anxiety Inventory (BAI): change from baseline to 12 weeks and from baseline to 24 weeks
Beck Depression Inventory 2nd Edition (BDI-II): change from baseline to 12 weeks and from baseline to 24 weeks
Multiple Sclerosis
+5 moreTACT-MS Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
Group II: Waitlist ControlActive Control1 Intervention
Find a Location
Who is running the clinical trial?
State University of New York at BuffaloLead Sponsor
248 Previous Clinical Trials
49,481 Total Patients Enrolled
11 Trials studying Multiple Sclerosis
3,236 Patients Enrolled for Multiple Sclerosis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have been diagnosed with Multiple Sclerosis.Your score for conscientiousness on the NEO-FFI test is much lower than the average score for healthy adults.Your score for conscientiousness on the NEO-FFI test is higher than 40.You are currently employed full- or part-time.You are above 18 years of age.\nYou have been diagnosed with Multiple Sclerosis.
Research Study Groups:
This trial has the following groups:- Group 1: Intervention
- Group 2: Waitlist Control
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Multiple Sclerosis Patient Testimony for trial: Trial Name: NCT04953689 — N/A
Share this study with friends
Copy Link
Messenger